{"id":819398,"date":"2025-02-27T13:04:13","date_gmt":"2025-02-27T18:04:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/mallinckrodt-plc-to-report-fourth-quarter-and-fiscal-year-2024-financial-results\/"},"modified":"2025-02-27T13:04:13","modified_gmt":"2025-02-27T18:04:13","slug":"mallinckrodt-plc-to-report-fourth-quarter-and-fiscal-year-2024-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mallinckrodt-plc-to-report-fourth-quarter-and-fiscal-year-2024-financial-results\/","title":{"rendered":"Mallinckrodt plc to Report Fourth Quarter and Fiscal Year 2024 Financial Results"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">DUBLIN<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Feb. 27, 2025<\/span><\/span> \/PRNewswire\/ &#8212; <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4371116-1&amp;h=2312389370&amp;u=https%3A%2F%2Fwww.mallinckrodt.com%2F&amp;a=Mallinckrodt+plc\" target=\"_blank\" rel=\"nofollow\"><u><span class=\"xn-org\">Mallinckrodt<\/span> plc<\/u><\/a>, a global specialty pharmaceutical company, today announced that it will report its fourth quarter and fiscal year 2024 financial results on <span class=\"xn-chron\">Tuesday, March 11<\/span>, 2025.\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/167103\/mallinckrodt_plc_logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/167103\/mallinckrodt_plc_logo.jpg\" title=\"Mallinckrodt logo\" alt=\"Mallinckrodt logo\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>A conference call for investors will begin at <span class=\"xn-chron\">8:00 a.m. ET<\/span> and can be accessed as follows:<\/p>\n<ul type=\"disc\">\n<li>Live Call Participant Registration (including dial-in):\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4371116-1&amp;h=1013643103&amp;u=https%3A%2F%2Fregister.vevent.com%2Fregister%2FBIf17087938ddc47079bf48d6d5e7c5687&amp;a=https%3A%2F%2Fregister.vevent.com%2Fregister%2FBIf17087938ddc47079bf48d6d5e7c5687\" target=\"_blank\" rel=\"nofollow\">https:\/\/register.vevent.com\/register\/BIf17087938ddc47079bf48d6d5e7c5687<\/a><\/li>\n<li>Audio Only Webcast Link (live and replay): <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4371116-1&amp;h=4067605657&amp;u=https%3A%2F%2Furldefense.com%2Fv3%2F__https%3A%2Fedge.media-server.com%2Fmmc%2Fp%2Figfp4swa__%3B!!NSSW2oN-0W-Y6e_0!ylCCqecVoJAjBcTZKF3yBzHy9nlT9IJtL7Cw6aKvB6hKWB8OYHsIbLl-Y6XKhZosDnS8fcqFI3Cp5ihWleSb3YYgOFq0%24&amp;a=https%3A%2F%2Fedge.media-server.com%2Fmmc%2Fp%2Figfp4swa\" target=\"_blank\" rel=\"nofollow\">https:\/\/edge.media-server.com\/mmc\/p\/igfp4swa<\/a><\/li>\n<li>\n          <span>On the Investor Relations page of<\/span>\u00a0the Mallinckrodt\u00a0website: <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4371116-1&amp;h=2264773849&amp;u=https%3A%2F%2Fir.mallinckrodt.com%2F&amp;a=https%3A%2F%2Fir.mallinckrodt.com%2F\" target=\"_blank\" rel=\"nofollow\">https:\/\/ir.mallinckrodt.com\/<\/a><\/li>\n<\/ul>\n<p>\n        <b>ABOUT <span class=\"xn-org\">MALLINCKRODT<\/span><br \/><\/b><br \/>\n        <span class=\"xn-org\">Mallinckrodt<\/span> is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The Company&#8217;s Specialty Brands reportable segment&#8217;s areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, and ophthalmology; neonatal respiratory critical care therapies; and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about <span class=\"xn-org\">Mallinckrodt<\/span>, visit<u><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4371116-1&amp;h=28829195&amp;u=https%3A%2F%2Fwww.mallinckrodt.com%2F&amp;a=www.mallinckrodt.com\" target=\"_blank\" rel=\"nofollow\">www.mallinckrodt.com<\/a><\/u>.\u00a0<\/p>\n<p>\n        <span class=\"xn-org\">Mallinckrodt<\/span> uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the Company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.<\/p>\n<p>\n        <b><br \/>\n          <u>Investor Relations Contact<br \/><\/u><br \/>\n        <\/b><br \/>\n        <span class=\"xn-person\">Derek Belz<\/span><br \/>\n        <br \/>Vice President, Investor Relations<br \/>314-654-3950<br \/><a href=\"mailto:derek.belz@mnk.com\" target=\"_blank\" rel=\"nofollow\">derek.belz@mnk.com<\/a><\/p>\n<p>\n        <span class=\"xn-org\">Mallinckrodt<\/span>, the &#8220;M&#8221; brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a <span class=\"xn-org\">Mallinckrodt<\/span> company. \u00a9 2025.<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=CG28211&amp;sd=2025-02-27\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/mallinckrodt-plc-to-report-fourth-quarter-and-fiscal-year-2024-financial-results-302387746.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/mallinckrodt-plc-to-report-fourth-quarter-and-fiscal-year-2024-financial-results-302387746.html<\/a><\/p>\n<p>SOURCE  <span class=\"xn-org\">Mallinckrodt<\/span> plc<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=CG28211&amp;Transmission_Id=202502271300PR_NEWS_USPR_____CG28211&amp;DateId=20250227\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire DUBLIN , Feb. 27, 2025 \/PRNewswire\/ &#8212; Mallinckrodt plc, a global specialty pharmaceutical company, today announced that it will report its fourth quarter and fiscal year 2024 financial results on Tuesday, March 11, 2025.\u00a0 A conference call for investors will begin at 8:00 a.m. ET and can be accessed as follows: Live Call Participant Registration (including dial-in):\u00a0https:\/\/register.vevent.com\/register\/BIf17087938ddc47079bf48d6d5e7c5687 Audio Only Webcast Link (live and replay): https:\/\/edge.media-server.com\/mmc\/p\/igfp4swa On the Investor Relations page of\u00a0the Mallinckrodt\u00a0website: https:\/\/ir.mallinckrodt.com\/ ABOUT MALLINCKRODT Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The Company&#8217;s Specialty Brands reportable segment&#8217;s areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mallinckrodt-plc-to-report-fourth-quarter-and-fiscal-year-2024-financial-results\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Mallinckrodt plc to Report Fourth Quarter and Fiscal Year 2024 Financial Results&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-819398","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Mallinckrodt plc to Report Fourth Quarter and Fiscal Year 2024 Financial Results - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mallinckrodt-plc-to-report-fourth-quarter-and-fiscal-year-2024-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mallinckrodt plc to Report Fourth Quarter and Fiscal Year 2024 Financial Results - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire DUBLIN , Feb. 27, 2025 \/PRNewswire\/ &#8212; Mallinckrodt plc, a global specialty pharmaceutical company, today announced that it will report its fourth quarter and fiscal year 2024 financial results on Tuesday, March 11, 2025.\u00a0 A conference call for investors will begin at 8:00 a.m. ET and can be accessed as follows: Live Call Participant Registration (including dial-in):\u00a0https:\/\/register.vevent.com\/register\/BIf17087938ddc47079bf48d6d5e7c5687 Audio Only Webcast Link (live and replay): https:\/\/edge.media-server.com\/mmc\/p\/igfp4swa On the Investor Relations page of\u00a0the Mallinckrodt\u00a0website: https:\/\/ir.mallinckrodt.com\/ ABOUT MALLINCKRODT Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The Company&#8217;s Specialty Brands reportable segment&#8217;s areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, &hellip; Continue reading &quot;Mallinckrodt plc to Report Fourth Quarter and Fiscal Year 2024 Financial Results&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/mallinckrodt-plc-to-report-fourth-quarter-and-fiscal-year-2024-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-27T18:04:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/167103\/mallinckrodt_plc_logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mallinckrodt-plc-to-report-fourth-quarter-and-fiscal-year-2024-financial-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mallinckrodt-plc-to-report-fourth-quarter-and-fiscal-year-2024-financial-results\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Mallinckrodt plc to Report Fourth Quarter and Fiscal Year 2024 Financial Results\",\"datePublished\":\"2025-02-27T18:04:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mallinckrodt-plc-to-report-fourth-quarter-and-fiscal-year-2024-financial-results\\\/\"},\"wordCount\":343,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mallinckrodt-plc-to-report-fourth-quarter-and-fiscal-year-2024-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/167103\\\/mallinckrodt_plc_logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mallinckrodt-plc-to-report-fourth-quarter-and-fiscal-year-2024-financial-results\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mallinckrodt-plc-to-report-fourth-quarter-and-fiscal-year-2024-financial-results\\\/\",\"name\":\"Mallinckrodt plc to Report Fourth Quarter and Fiscal Year 2024 Financial Results - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mallinckrodt-plc-to-report-fourth-quarter-and-fiscal-year-2024-financial-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mallinckrodt-plc-to-report-fourth-quarter-and-fiscal-year-2024-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/167103\\\/mallinckrodt_plc_logo.jpg\",\"datePublished\":\"2025-02-27T18:04:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mallinckrodt-plc-to-report-fourth-quarter-and-fiscal-year-2024-financial-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mallinckrodt-plc-to-report-fourth-quarter-and-fiscal-year-2024-financial-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mallinckrodt-plc-to-report-fourth-quarter-and-fiscal-year-2024-financial-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/167103\\\/mallinckrodt_plc_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/167103\\\/mallinckrodt_plc_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mallinckrodt-plc-to-report-fourth-quarter-and-fiscal-year-2024-financial-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mallinckrodt plc to Report Fourth Quarter and Fiscal Year 2024 Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mallinckrodt plc to Report Fourth Quarter and Fiscal Year 2024 Financial Results - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/mallinckrodt-plc-to-report-fourth-quarter-and-fiscal-year-2024-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"Mallinckrodt plc to Report Fourth Quarter and Fiscal Year 2024 Financial Results - Market Newsdesk","og_description":"PR Newswire DUBLIN , Feb. 27, 2025 \/PRNewswire\/ &#8212; Mallinckrodt plc, a global specialty pharmaceutical company, today announced that it will report its fourth quarter and fiscal year 2024 financial results on Tuesday, March 11, 2025.\u00a0 A conference call for investors will begin at 8:00 a.m. ET and can be accessed as follows: Live Call Participant Registration (including dial-in):\u00a0https:\/\/register.vevent.com\/register\/BIf17087938ddc47079bf48d6d5e7c5687 Audio Only Webcast Link (live and replay): https:\/\/edge.media-server.com\/mmc\/p\/igfp4swa On the Investor Relations page of\u00a0the Mallinckrodt\u00a0website: https:\/\/ir.mallinckrodt.com\/ ABOUT MALLINCKRODT Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The Company&#8217;s Specialty Brands reportable segment&#8217;s areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, &hellip; Continue reading \"Mallinckrodt plc to Report Fourth Quarter and Fiscal Year 2024 Financial Results\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/mallinckrodt-plc-to-report-fourth-quarter-and-fiscal-year-2024-financial-results\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-27T18:04:13+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/167103\/mallinckrodt_plc_logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mallinckrodt-plc-to-report-fourth-quarter-and-fiscal-year-2024-financial-results\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mallinckrodt-plc-to-report-fourth-quarter-and-fiscal-year-2024-financial-results\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Mallinckrodt plc to Report Fourth Quarter and Fiscal Year 2024 Financial Results","datePublished":"2025-02-27T18:04:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mallinckrodt-plc-to-report-fourth-quarter-and-fiscal-year-2024-financial-results\/"},"wordCount":343,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mallinckrodt-plc-to-report-fourth-quarter-and-fiscal-year-2024-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/167103\/mallinckrodt_plc_logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mallinckrodt-plc-to-report-fourth-quarter-and-fiscal-year-2024-financial-results\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/mallinckrodt-plc-to-report-fourth-quarter-and-fiscal-year-2024-financial-results\/","name":"Mallinckrodt plc to Report Fourth Quarter and Fiscal Year 2024 Financial Results - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mallinckrodt-plc-to-report-fourth-quarter-and-fiscal-year-2024-financial-results\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mallinckrodt-plc-to-report-fourth-quarter-and-fiscal-year-2024-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/167103\/mallinckrodt_plc_logo.jpg","datePublished":"2025-02-27T18:04:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mallinckrodt-plc-to-report-fourth-quarter-and-fiscal-year-2024-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/mallinckrodt-plc-to-report-fourth-quarter-and-fiscal-year-2024-financial-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mallinckrodt-plc-to-report-fourth-quarter-and-fiscal-year-2024-financial-results\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/167103\/mallinckrodt_plc_logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/167103\/mallinckrodt_plc_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mallinckrodt-plc-to-report-fourth-quarter-and-fiscal-year-2024-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Mallinckrodt plc to Report Fourth Quarter and Fiscal Year 2024 Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/819398","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=819398"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/819398\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=819398"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=819398"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=819398"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}